Revvity

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery
CompanyDeals

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Atavistik Bio announced a strategic research collaboration with Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) to discover and develop novel small molecule therapies targeting multiple targets in cardiovascular, renal, and…

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billio

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Revvity and Sanyou Biopharmaceuticals Deepen Partnership to Advance Biologic Drug Development